Yahoo · Oct 8, 2026
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash
RARE enters into an agreement to sell a Rare Pediatric Disease PRV for $210M, adding non-dilutive cash as it advances rare-disease therapies.
AL
NASDAQ · ALDX
Aldeyra Therapeutics, Inc.
Healthcare · Biotechnology
$0.62
Up+$0.03 (+4.32%)
Updated Nov 4, 2026, 11:41 PM
SID Score
4.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 328.49M
- P/E ratio
- -7.6
- Dividend yield
- 0.00%
- 52-week range
- $0.53 – $5.60
- Volume
- 671.06K
- Avg. volume
- 1.07M
Price performance · ALDX
ALDX price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
ALDX closed at $0.62 after 21 trading sessions, down 32.24% for the selected period.
- Last close
- $0.62
- Period change
- -32.24%
- Period low
- $0.56
- Period high
- $0.96
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $0.5832 | $0.63 | $0.5526 | $0.6206 | 671.06K |
| Nov 2, 2026 | $0.5601 | $0.5994 | $0.5271 | $0.5832 | 906.1K |
| Oct 30, 2026 | $0.67 | $0.68 | $0.5502 | $0.5603 | 896.63K |
| Oct 29, 2026 | $0.67 | $0.719 | $0.6556 | $0.6591 | 418.11K |
| Oct 28, 2026 | $0.64 | $0.6932 | $0.63 | $0.6836 | 727.58K |
| Oct 27, 2026 | $0.6311 | $0.6692 | $0.6203 | $0.6412 | 991.81K |
| Oct 26, 2026 | $0.6569 | $0.6698 | $0.6269 | $0.6417 | 786.36K |
| Oct 23, 2026 | $0.63 | $0.6544 | $0.6035 | $0.6497 | 821.84K |
| Oct 22, 2026 | $0.6704 | $0.7346 | $0.6278 | $0.6453 | 717.82K |
| Oct 21, 2026 | $0.7375 | $0.7499 | $0.6601 | $0.6703 | 606.57K |
| Oct 20, 2026 | $0.654 | $0.7484 | $0.6501 | $0.7343 | 1.65M |
| Oct 19, 2026 | $0.7042 | $0.72 | $0.656 | $0.6651 | 861.77K |
| Oct 16, 2026 | $0.74 | $0.74 | $0.6501 | $0.7001 | 1.81M |
| Oct 15, 2026 | $0.77 | $0.803 | $0.7254 | $0.7373 | 1.23M |
| Oct 14, 2026 | $0.88 | $0.899 | $0.7886 | $0.7904 | 1.58M |
| Oct 13, 2026 | $0.89 | $0.91 | $0.8652 | $0.8998 | 1.46M |
| Oct 12, 2026 | $0.92 | $0.94 | $0.882 | $0.9058 | 1.34M |
| Oct 9, 2026 | $0.9396 | $0.97 | $0.915 | $0.9163 | 699.27K |
| Oct 8, 2026 | $0.96 | $0.97 | $0.9124 | $0.9477 | 1.18M |
| Oct 7, 2026 | $0.91 | $0.9666 | $0.8812 | $0.9586 | 1.29M |
| Oct 6, 2026 | $0.95 | $0.99 | $0.8619 | $0.9159 | 8.23M |
Latest ALDX news
The latest Smart Investors Daily articles mentioning ALDX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ALDX research
Overview
Company profile and research snapshot.
Company profile
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $7.00
- Implied upside
- —
- Analysts
- 12
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 30, 2026 | HC Wainwright & Co. | Neutral | — |
| Sep 29, 2026 | BTIG | Buy | — |
| Mar 18, 2026 | HC Wainwright & Co. | Neutral | — |
| Nov 10, 2025 | BTIG | Buy | — |
| May 19, 2025 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Sep 30, 2026
HC Wainwright & Co. Reiterates Neutral on Aldeyra Therapeutics, Maintains $2 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Neutral and maintains $2 price target.
SeekingAlpha · Sep 30, 2026
Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease - Slideshow
Yahoo · Sep 29, 2026
Aldeyra to Appeal FDA Rejection of Reproxalap for Dry Eye Disease
Aldeyra Therapeutics (NASDAQ:ALDX) said it plans to submit a formal dispute resolution request, or FDRR, to the FDA’s Office of New Drugs seeking review of the agency’s latest complete response letter for reproxalap, its investigational treatment for the signs and symptoms of dry eye disease. The c
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
